The estimated Net Worth of Scott B Townsend is at least $512 millier dollars as of 14 May 2009. Scott Townsend owns over 44,972 units of Cortexyme Inc stock worth over $220,434 and over the last 20 years Scott sold CRTX stock worth over $291,419.
Scott has made over 2 trades of the Cortexyme Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Scott sold 44,972 units of CRTX stock worth $291,419 on 14 May 2009.
The largest trade Scott's ever made was selling 44,972 units of Cortexyme Inc stock on 14 May 2009 worth over $291,419. On average, Scott trades about 2,420 units every 70 days since 2005. As of 14 May 2009 Scott still owns at least 113,043 units of Cortexyme Inc stock.
You can see the complete history of Scott Townsend stock trades at the bottom of the page.
Scott's mailing address filed with the SEC is C/O CRITICAL THERAPEUTICS, INC., 60 WESTVIEW STREET, LEXINGTON, MA, 02421.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi et Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: